Recent weeks have seen Sidley Austin shed two life sciences patent litigators in New York shortly after hiring a new transactional specialist on the West Coast. Dechert, meanwhile, has added to its own IP disputes team with a hire from Hughes Hubbard & Reed.

⇒ Patent litigators Bindu Donovan and Todd Krause left Sidley Austin for New York IP boutique Desmarais on 15 October.

The pair focus on representing pharmaceutical companies against generic and biosimilar competitors, particularly in lawsuits filed under the Hatch-Waxman Act. These include representing Johnson & Johnson subsidiary Janssen in suits involving its cancer drug Zytiga and Gilead and Roche in a suit concerning flu treatment Tamiflu.

Donovan, who spent 10 years as a partner at Sidley, told PLN “Desmarais is one of the industry’s elite litigation boutiques, and I’m very excited about the opportunity to participate in the expansion of its life sciences practice.”

“Desmarais is a leader in high-stakes patent litigation,” Krause added, saying he too was excited to join its ranks.

Sidley told PLN in a statement “we wish them well.”

Donovan and Krause’s departure comes shortly after King & Spalding partner Thomas Duley joined Sidley’s global life sciences practice in its San Francisco office.

A transactional specialist, Duley represented protein therapy start-up Nurix in its collaboration with Celgene Corporation for the production of small molecule therapeutics in oncology, inflammation and immunology. He also represented dermatology drugmaker Dermira when it obtained exclusive rights from Hoffman-La Roche and Genentech to manufacture an antibody for atopic dermatitis.

Duley spent almost five years as a partner at King & Spalding, prior to which he was of counsel at DLA Piper and Morgan Lewis & Bockius.

“The Sidley platform allows me to support biotechnology and medical device clients with professionals in M&A and capital markets, as well as an extraordinary FDA/Regulatory practice,” Duley told PLN.

Fritz Zimmer, managing partner of King & Spalding’s San Francisco office, said “Tom has been a great colleague, and we appreciate the contributions he has made to the firm.”

⇒ Dechert recruited Stephen Rabinowitz from Hughes Hubbard & Reed in New York on 12 October.

His practice focuses on patent litigation, specifically within the domains of life sciences and pharmaceuticals.

He represented Hoffman-La Roche in a US patent litigation concerning a pharmaceutical treatment for HIV infections that had progressed to AIDS.

He has also acted for Roche and LabCorp against Novartis in separate US patent proceedings concerning the detection of hepatitis C, and counselled Merck in a dispute with Gilead over the US patent for a highly successful pharmaceutical treatment for the same condition.

“Stephen’s wide-ranging expertise combined with his unique medical experience will bring a new perspective to the team as we continue to navigate sophisticated IP issues for life sciences companies,” said Jeffrey Plies, chair of Dechert’s IP practice group in a press release.

Rabinowitz spent four years at Hughes Hubbard, prior to which he was a partner at Fried Frank in New York for a decade.

“I had been talking to colleagues at Dechert that I’ve known for more than 20 years,” Rabinowitz told PLN. “I was very impressed by the depth and strength of Dechert’s expertise in the life sciences.”